{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["An SJ"],"funding":["Lineberger Comprehensive Cancer Center Core Support Grant","NCI NIH HHS","NIH HHS"],"pubmed_abstract":["<h4>Background</h4>Nodal pathologic complete response (npCR) after neoadjuvant treatment in patients with node-positive breast cancer (BC) avoids the morbidity of axillary dissection. In this study, we aimed to identify predictors of npCR.<h4>Patients and methods</h4>Adult women with stage 2-3 BC and clinically positive nodes from 2011 to 2021 in the National Cancer Database who received neoadjuvant chemotherapy followed by surgery within 8 months were included. Predictors of npCR were modeled with multivariable logistic regression.<h4>Results</h4>In total, 47,483 patients were included: 18,978 (40.0%) with npCR and 28,505 (60.0%) with nodal residual disease (nRD). Median age for the npCR group was 53 years (interquartile range [IQR] 21-90 years) compared with 54 years (IQR 21-90 years, p < 0.001) in the nRD group. Triple negative breast cancer (TNBC) was the most common subtype (53.5%) in the npCR group while ER+/HER2- was the most common (46.5%) in the nRD group, p < 0.001. After adjusting for sociodemographic factors, comorbidities, tumor characteristics, and treatment, younger age (odds ratio [OR] 0.99, 95% confidence interval [CI] 0.99-0.99), ER-/HER2+ compared with TNBC (OR 1.32, 95% CI 1.21-1.44), and receipt of immunotherapy (OR 1.60, 95% CI 1.46-1.74) were associated with npCR. Black patients were less likely to have npCR overall (OR 0.90, 95% CI 0.85-0.95) with TNBC and HER2+ tumors, but more likely in ER+/HER2- tumors.<h4>Conclusions</h4>Both tumor and sociodemographic factors were associated with npCR in patients with BC. Black compared with white patients were more likely to have npCR in the ER+/HER2- subtype but less likely in the hormone receptor-negative and HER2+ subtypes. Mechanisms underlying these differences should be further investigated."],"journal":["Annals of surgical oncology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12371429"],"repository":["biostudies-literature"],"pubmed_title":["Predictors of Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer."],"pmcid":["PMC12371429"],"funding_grant_id":["R37CA292075","P30CA016086","P30 CA016086","K08CA280388","R37 CA292075","K08 CA280388"],"pubmed_authors":["Abdou YG","Selfridge JM","Thai CHNC","Spanheimer PM","An SJ","Agala CB"],"additional_accession":[]},"is_claimable":false,"name":"Predictors of Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer.","description":"<h4>Background</h4>Nodal pathologic complete response (npCR) after neoadjuvant treatment in patients with node-positive breast cancer (BC) avoids the morbidity of axillary dissection. In this study, we aimed to identify predictors of npCR.<h4>Patients and methods</h4>Adult women with stage 2-3 BC and clinically positive nodes from 2011 to 2021 in the National Cancer Database who received neoadjuvant chemotherapy followed by surgery within 8 months were included. Predictors of npCR were modeled with multivariable logistic regression.<h4>Results</h4>In total, 47,483 patients were included: 18,978 (40.0%) with npCR and 28,505 (60.0%) with nodal residual disease (nRD). Median age for the npCR group was 53 years (interquartile range [IQR] 21-90 years) compared with 54 years (IQR 21-90 years, p < 0.001) in the nRD group. Triple negative breast cancer (TNBC) was the most common subtype (53.5%) in the npCR group while ER+/HER2- was the most common (46.5%) in the nRD group, p < 0.001. After adjusting for sociodemographic factors, comorbidities, tumor characteristics, and treatment, younger age (odds ratio [OR] 0.99, 95% confidence interval [CI] 0.99-0.99), ER-/HER2+ compared with TNBC (OR 1.32, 95% CI 1.21-1.44), and receipt of immunotherapy (OR 1.60, 95% CI 1.46-1.74) were associated with npCR. Black patients were less likely to have npCR overall (OR 0.90, 95% CI 0.85-0.95) with TNBC and HER2+ tumors, but more likely in ER+/HER2- tumors.<h4>Conclusions</h4>Both tumor and sociodemographic factors were associated with npCR in patients with BC. Black compared with white patients were more likely to have npCR in the ER+/HER2- subtype but less likely in the hormone receptor-negative and HER2+ subtypes. Mechanisms underlying these differences should be further investigated.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-05-08T10:43:15.07Z","creation":"2026-04-07T23:46:47.868Z"},"accession":"S-EPMC12371429","cross_references":{"pubmed":["40684017"],"doi":["10.1245/s10434-025-17906-5"]}}